About HDT BIO CORP
HDT Bio is a clinical-stage private company developing advanced products to treat and prevent cancer and infectious diseases using its proprietary LION™ technology. The company focuses on immune-enhancing solutions for global health, biodefense, and oncology.
Development of advanced products for cancer and infectious diseasesUtilization of proprietary LION™ technology for superior safety, potency, durability, and manufacturing advantagesCreation of next-generation formulations with increased potency, safety, tolerability, immunogenicity, and manufacturability
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| ADAPTABLE RNA-BASED ANTIBODY PLATFORM FOR PROTECTION AGAINST CONTEMPORARY/EMERGING HUMAN ENTEROVIRUSES | Department of Health and Human Services | $1.5M | |
| HDT BIO CORP - AOI #21 VACCINE ON DEMAND: R&D USE OF LION-REPRNA IN RAPID RESPONSE VACCINE DEVELOPMENT | Department of Health and Human Services | $749K | |
| COVID-19. TO DEVELOP AND PROGRESS HDT-301, A REPLICON RNA ENCODING SARS-COV-2 SPIKE PROTEIN BOUND TO LIPID INO | Department of Health and Human Services | $11.0M | |
| Federal contract award | Department of Health and Human Services | $600K | |
| RESEARCH SERVICE | Department of Defense | $129K |
Teaming History
Prime contractors HDT BIO CORP has worked under:
- Mriglobal — 4 subcontract(s)
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to HDT BIO CORP right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.